Akero Therapeutics DEF 14A: Executive Compensation Details
| Field | Detail |
|---|---|
| Company | Akero Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, equity-awards, sec-filing
TL;DR
Akero's DEF 14A is out, showing exec pay details for 2021-2023. Focus on equity awards.
AI Summary
Akero Therapeutics, Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation and equity awards for the fiscal years ending December 31, 2021, 2022, and 2023. The filing includes information on changes in the fair value of outstanding equity awards granted in prior years and equity awards granted in the summary compensation table for applicable years. Specific dollar amounts and names of executives are not detailed in the provided snippet.
Why It Matters
This filing provides transparency into how Akero Therapeutics compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings, while routine, can reveal significant information about executive compensation and potential shareholder concerns, impacting stock valuation.
Key Players & Entities
- Akero Therapeutics, Inc. (company) — Filer of the DEF 14A
- 20250428 (date) — Filing date of the DEF 14A
- 2021-12-31 (date) — Fiscal year end for compensation data
- 2022-12-31 (date) — Fiscal year end for compensation data
- 2023-12-31 (date) — Fiscal year end for compensation data
FAQ
What is the primary purpose of this DEF 14A filing for Akero Therapeutics?
The primary purpose is to provide detailed information regarding the compensation of Akero Therapeutics' named executive officers and directors, as well as other corporate governance matters, for the fiscal year ending December 31, 2023.
What fiscal years are covered by the compensation data in this filing?
The compensation data and related equity award information in this filing primarily cover the fiscal years ending December 31, 2021, 2022, and 2023.
What specific types of executive compensation are detailed in the filing?
The filing details executive compensation including changes in the fair value of outstanding equity awards granted in prior years and equity awards granted in the summary compensation table for applicable years.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 28, 2025.
What is Akero Therapeutics' Standard Industrial Classification (SIC) code?
Akero Therapeutics' Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 regarding Akero Therapeutics, Inc..